Using the short term ex-vivo treatment protocol we established that: 1) 3 μM of Selumetinib inhibits pERK1/2 phosphorylation in all tumours and the effect is independent of whether or not tumours harbour a KRAS or BRAF mutation. Here, BRAF is linked to neoplasm.